Elkan F. Halpern

Elkan F. Halpern

Auto-generated profile, based on publicly available information

Elkan F. Halpern

Institute for Technology Assessment, 101 Merrimac St., Boston, MA 02114, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in European Journal of Radiology
Verified
Journal Article
Closed access
JAJeanne B. Ackman
Jeanne B. Ackman
SVStacey Verzosa
Stacey Verzosa
AKAlexandra E. Kovach
Alexandra E. Kovach
ALAbner Louissaint
Abner Louissaint
MLMichael Lanuti
Michael Lanuti
EHElkan F. Halpern
Elkan F. Halpern

5 March 2004 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
RFRobert A Fuller
Robert A Fuller
SWSusan V Westmoreland
Susan V Westmoreland
EREva Ratai
Eva Ratai
JGJane B Greco
Jane B Greco
JKJohn P Kim
John P Kim
RGR Gilberto González
R Gilberto González
The neurological complications of HIV infection remain poorly understood. Clinically, in vivo 1H magnetic resonance spectroscopy (MRS) demonstrates brain injury caused by HIV infection even when the MRI is normal. Our goal was to undertsand the dynamics of cerebral injury by performing a longitudinal in vivo 1H MRS study of the SIV/macaque model of neuroAIDS. Eight rhesus macaques were infected with SIVmac251 and serially imaged with MRI and 1H MRS to terminal AIDS or the endpoint of 2 years. During acute infection, there were stereotypical brain MRS changes, dominated by a significant elevation of the Cho/Cr ratio in the frontal cortex. Subsequently, brain metabolic patterns diverged between animals. There was an elevation of basal ganglia Cho/Cr four weeks post-inoculation in 2 animals that developed SIV encephalitis (p = 0.022). Metabolite ratios averaged across all 8 animals were not significantly different from baseline at any time point after 2 weeks post inoculation. However, linear regression analysis on all 8 animals revealed a positive correlation between a change in frontal lobe Cho/Cr and plasma viral load (P < 0.001, R = 0.80), and a negative correlation between NAA/Cr in the basal ganglia and the plasma viral load (P < 0.02, R = -0.73). No MRI abnormalities were detected at any time. After infection with SIV, macaque brain metabolism changes in a complex manner that is dependent on brain region, host factors and viral load. An elevation of basal ganglia Cho/Cr 4 weeks after SIV infection may be marker of a propensity to develop SIV encephalitis. Elevations of Cho/Cr, often observed in CNS inflammation, were associated with increased plasma viral load during acute and chronic infection. Evidence of neuronal injury in the basal ganglia was associated with increased plasma viral load in the chronic stage of infection. These observations support the use of drugs capable of controlling the viral replication and trafficking of virus into the CNS, and may help explain the reduction in incidence of HIV-associated dementia in the era of HAART despite the inability of most of those drugs to effectively enter the CNS.

1 September 2014 in Journal of the American College of Radiology
Verified
Journal Article
Closed access
BNBethany L. Niell
Bethany L. Niell
SGSara C. Gavenonis
Sara C. Gavenonis
TMTina Motazedi
Tina Motazedi
JCJessica Cott Chubiz
Jessica Cott Chubiz
EHElkan P. Halpern
Elkan P. Halpern
JLJanie M. Lee
Janie M. Lee

22 June 2009 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
EREva-Maria Ratai
Eva-Maria Ratai
SPSarah J Pilkenton
Sarah J Pilkenton
JGJane B Greco
Jane B Greco
MLMargaret R Lentz
Margaret R Lentz
JBJeffrey P Bombardier
Jeffrey P Bombardier
RGR Gilberto González
R Gilberto González
Background: In vivo proton magnetic resonance spectroscopy (1H-MRS) studies of HIV-infected humans have demonstrated significant metabolic abnormalities that vary by brain region, but the causes are poorly understood. Metabolic changes in the frontal cortex, basal ganglia and white matter in 18 SIV-infected macaques were investigated using MRS during the first month of infection. Results: Changes in the N-acetylaspartate (NAA), choline (Cho), myo-inositol (MI), creatine (Cr) and glutamine/glutamate (Glx) resonances were quantified both in absolute terms and relative to the creatine resonance. Most abnormalities were observed at the time of peak viremia, 2 weeks post infection (wpi). At that time point, significant decreases in NAA and NAA/Cr, reflecting neuronal injury, were observed only in the frontal cortex. Cr was significantly elevated only in the white matter. Changes in Cho and Cho/Cr were similar across the brain regions, increasing at 2 wpi, and falling below baseline levels at 4 wpi. MI and MI/Cr levels were increased across all brain regions. Conclusion: These data best support the hypothesis that different brain regions have variable intrinsic vulnerabilities to neuronal injury caused by the AIDS virus.

8 February 2018 in Gait & Posture
Verified
Journal Article
Open access
PDF file
FBFrancois Bethoux
Francois Bethoux
JVJonathan S. Varsanik
Jonathan S. Varsanik
TCTimothy W. Chevalier
Timothy W. Chevalier
EHElkan F. Halpern
Elkan F. Halpern
DSDarlene Stough
Darlene Stough
ZKZebadiah M. Kimmel
Zebadiah M. Kimmel
Walking speed is an important measure of gait impairment in multiple sclerosis (MS). The clinical assessment of walking speed requires dedicated time, space, and personnel, and may not accurately gauge real-world performance. The term “Ambient Measurement System” (AMS) refers to a new class of device that passively measures walking speed at home, without the need for dedicated space or specialized setup. This study compared an AMS, Echo5D, versus in-clinic standard measures of walking speed on a straight path. Twenty participants with MS and walking impairment were recruited from the Cleveland Clinic Mellen Center for MS. Each participant traversed an electronic GAITRite CIRFace (GC) sensor mat four times (two at comfortable pace, two at fast pace). Each participant then performed the Timed 25-Foot Walk (T25FW) twice, measured by a manual stopwatch (SW). All traversals were simultaneously measured by an array of Echo5D devices. Echo5D speeds were correlated with the Patient-Determined Disease Steps and the MS Walking Scale-12 patient-reported outcomes. Pearson correlations between Echo5D and clinical tests ranged from 0.89 to 0.98 (p < 0.0001). No statistically significant bias was found between Echo5D and GC. A small statistically significant bias was found between Echo5D and SW, with Echo5D reporting approximately 5% faster walking speeds in aggregate. Among MS patients with walking impairments, the Echo5D AMS acquired walking speeds which were closely correlated with the standard measures of GC and SW. The strong agreement supports the use of Echo5D to assess in-home, real-world walking performance in MS.